1
Clinical Trials associated with Irinotecan Hydrochloride Lioposome (Kelun)盐酸伊立替康脂质体注射液在晚期实体瘤患者中的安全性、耐受性及药代动力学特征的Ⅰa期临床研究
[Translation] Phase Ia clinical study on the safety, tolerability and pharmacokinetic characteristics of irinotecan hydrochloride liposome injection in patients with advanced solid tumors
评估盐酸伊立替康脂质体注射液在晚期实体瘤患者中的安全性和耐受性,确定剂量限制性毒性和最大耐受剂量;评估晚期实体瘤患者静脉滴注盐酸伊立替康脂质体注射液后的药代动力学特征;比较盐酸伊立替康脂质体注射液与盐酸伊立替康注射液的药代动力学差异;观察本品的初步疗效
[Translation] To evaluate the safety and tolerability of irinotecan hydrochloride liposome injection in patients with advanced solid tumors, determine the dose-limiting toxicity and maximum tolerated dose; to evaluate the pharmacokinetic characteristics of irinotecan hydrochloride liposome injection in patients with advanced solid tumors after intravenous infusion; to compare the pharmacokinetic differences between irinotecan hydrochloride liposome injection and irinotecan hydrochloride injection; to observe the preliminary efficacy of this product
100 Clinical Results associated with Irinotecan Hydrochloride Lioposome (Kelun)
100 Translational Medicine associated with Irinotecan Hydrochloride Lioposome (Kelun)
100 Patents (Medical) associated with Irinotecan Hydrochloride Lioposome (Kelun)
100 Deals associated with Irinotecan Hydrochloride Lioposome (Kelun)